EYPT - EyePoint Pharma reports positive EYP-1901 data for treatment of wet AMD

EyePoint Pharmaceuticals (NASDAQ:EYPT) announces six-month interim data from the DAVIO Phase 1 clinical trial of EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD). The data were presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting. Six-month interim data from the Phase 1 DAVIO clinical trial show no reports of ocular serious adverse events (SAEs) or drug-related systemic SAEs. 76% and 53% of patients were rescue-free up to four and six months, respectively, following a single injection of EYP-1901. Stable best corrected visual acuity (BCVA), -2.5 letters, and central subfield thickness, -2.7 ?m, were achieved at the six-month visits. Overall treatment burden reduced by 79% at six months. EyePoint plans to initiate a Phase 2 wet AMD clinical trial in 2022 and the Company has scheduled a Type C meeting with the FDA on December 1, 2021, to discuss specific plans and obtain guidance on potential EYP-1901

For further details see:

EyePoint Pharma reports positive EYP-1901 data for treatment of wet AMD